Literature DB >> 17606212

Management of hepatitis C virus in the transplant patient.

Marina Berenguer1.   

Abstract

Hepatitis C virus (HCV) is a leading cause of chronic hepatitis, with 170 to 190 million people infected worldwide. The treatment of choice for patients who have HCV-related cirrhosis with or without hepatocellular carcinoma is liver transplantation. Virologic recurrence is constant after transplantation and results in chronic hepatitis in the vast majority. HCV infection now can be cured in a substantial proportion of liver transplant recipients. This review highlights the available strategies to improve outcome, including modification of factors that affect disease progression and the efficacy of antiviral therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17606212     DOI: 10.1016/j.cld.2007.04.010

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  4 in total

1.  New and Evolving Management Paradigms for Hepatitis C after Liver Transplantation.

Authors:  A Sidney Barritt; Jama M Darling; Paul H Hayashi
Journal:  Curr Hepat Rep       Date:  2011-09

Review 2.  Bioconjugation of oligonucleotides for treating liver fibrosis.

Authors:  Zhaoyang Ye; Houssam S Hajj Houssein; Ram I Mahato
Journal:  Oligonucleotides       Date:  2007

3.  Hepatitis C and kidney transplantation.

Authors:  Marco Carbone; Paul Cockwell; James Neuberger
Journal:  Int J Nephrol       Date:  2011-06-28

4.  Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir.

Authors:  P Badri; S Dutta; E Coakley; D Cohen; B Ding; T Podsadecki; B Bernstein; W Awni; R Menon
Journal:  Am J Transplant       Date:  2015-02-23       Impact factor: 8.086

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.